Mounjaro (tirzepatide) is generally considered safe for most adults when used as prescribed, but it comes with a range of side effects that vary from mild digestive discomfort to rare but serious complications. In clinical trials involving thousands of participants, most people tolerated the medication well enough to continue treatment, and the FDA has approved it for type 2 diabetes and (under the brand name Zepbound) for weight management. That said, the drug carries a boxed warning about thyroid tumor risk, and several side effects deserve your attention before starting.
Common Side Effects
The most frequent complaints are gastrointestinal: reduced appetite, nausea, and diarrhea, each affecting roughly 10% of patients in clinical trials. Vomiting, acid reflux, and constipation also occur but less often. These symptoms tend to be worst during the first few weeks and when the dose increases. They typically improve as your body adjusts.
Mounjaro’s dosing schedule is specifically designed to limit these effects. You start at 2.5 mg once a week, a dose too low to provide meaningful blood sugar control, purely to let your body acclimate. After four weeks, you move up to 5 mg. Further increases of 2.5 mg happen no sooner than every four weeks. Skipping ahead or escalating too quickly makes nausea and diarrhea significantly more likely.
The Thyroid Tumor Warning
Mounjaro’s most prominent safety concern is its FDA boxed warning about thyroid C-cell tumors. In two-year rat studies, tirzepatide caused a dose-dependent increase in thyroid tumors at doses comparable to what humans receive. Whether this translates to humans is unknown, and no confirmed link to thyroid cancer in people has been established. Still, the FDA treats this seriously enough to make it the drug’s most visible warning.
Because of this uncertainty, Mounjaro is completely off-limits if you or a blood relative have ever had medullary thyroid carcinoma, or if you have a genetic condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, shortness of breath, or persistent hoarseness while taking Mounjaro, those are the symptoms to flag immediately.
Gallbladder and Pancreas Risks
A systematic review and meta-analysis published in Frontiers in Endocrinology found that tirzepatide was associated with roughly double the risk of gallbladder or biliary disease compared to placebo or insulin. This elevated risk was statistically significant at the 10 mg dose, though interestingly not at the 5 mg or 15 mg doses. The types of gallbladder problems included gallstones and inflammation, which can cause sudden upper abdominal pain, especially after eating.
Pancreatitis, a more feared complication, did not show a statistically significant increase in the same analysis. The overall risk ratio was 1.46 compared to control groups, but the confidence interval was wide enough that the increase could be due to chance. Still, rapid weight loss from any cause is a known trigger for both gallstones and pancreatitis, so the risk isn’t zero.
Stomach Emptying and Digestive Slowdown
Mounjaro works partly by slowing how quickly food leaves your stomach, which helps control blood sugar and reduces hunger. For most people, this means feeling full longer. For a small number, it can tip into something more problematic. Research on the broader class of drugs Mounjaro belongs to found up to a 3.5-fold increased risk of intestinal obstruction in patients with type 2 diabetes, and a fourfold increase in food remaining in the stomach during endoscopy procedures.
Severe gastroparesis, where the stomach essentially stops emptying, is rare but has been documented. A systematic review found that the average delay in stomach emptying was about 36 minutes, which is modest. But individual responses vary widely, and cases of acute gastric obstruction have been reported, particularly at lower doses early in treatment. If you experience persistent vomiting, severe bloating, or the inability to keep food down, that warrants prompt medical attention.
Kidney Injury From Dehydration
One underappreciated risk is kidney damage caused not by the drug itself but by the dehydration that severe nausea, vomiting, or diarrhea can trigger. Case reports have documented acute kidney failure in patients without any prior kidney disease, with the damage traced directly to fluid loss from persistent GI symptoms. In one published case, a patient’s kidney function deteriorated enough that a nephrologist was consulted, though dialysis was ultimately unnecessary after aggressive fluid replacement.
This makes staying hydrated especially important during the early weeks and during dose increases, when GI side effects are most intense. If you’re unable to keep fluids down for more than a day, that’s a situation that needs medical attention before kidney function is affected.
Low Blood Sugar Risk
Mounjaro on its own rarely causes dangerously low blood sugar. In the SURPASS-2 trial, hypoglycemia occurred in just 0.2% to 1.7% of patients taking tirzepatide with metformin alone. The risk climbs when Mounjaro is combined with insulin or sulfonylureas, medications that independently push blood sugar down. If you take any of these alongside Mounjaro, your prescriber will likely reduce the dose of the other medication to compensate.
Mental Health Concerns
Early reports raised questions about whether drugs in this class might increase suicidal thoughts. The FDA investigated and found no clear evidence of a link. Reviews of adverse event reports, clinical trials, large outcome studies, and observational data all came back without a demonstrable association. However, because the number of such events was small in both treatment and control groups, the FDA has not entirely closed the book. Prescribing labels for all weight-loss medications, including Mounjaro, carry standard language about monitoring for mood changes, which reflects a longstanding precaution across weight-loss drugs rather than a signal specific to tirzepatide.
Emerging Safety Signals
In early 2024, the FDA flagged a potential signal for dysesthesia, an abnormal sensation such as burning, tingling, or prickling on the skin, across the entire class of drugs that includes Mounjaro. The agency noted it was evaluating whether regulatory action was needed. This does not mean the drug causes dysesthesia, only that enough reports accumulated to warrant a closer look. No label changes had resulted from this signal at the time of the review.
Who Should Not Take Mounjaro
Beyond the thyroid cancer contraindication, Mounjaro is not appropriate for anyone with a known serious allergy to tirzepatide or any inactive ingredient in the injection. People with a history of pancreatitis should discuss the risks carefully with their provider, and those with severe gastrointestinal conditions may find that the drug’s effects on stomach emptying worsen their symptoms. Mounjaro has not been studied in combination with other tirzepatide-containing products or other drugs in the same class, so doubling up is not recommended.
For most people who meet the prescribing criteria, Mounjaro’s safety profile is manageable, particularly when the dose is increased gradually and GI symptoms are taken seriously rather than pushed through. The serious risks, while real, are uncommon enough that they didn’t prevent FDA approval across two separate indications. The key is knowing what to watch for so that the rare complications are caught early.